Teva down after predicting a 'trough' year ahead

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) lost $1.49 to $17.63 on NYSE Wednesday when the company reported a decrease in 4Q18 generics sales and introduced 2019 guidance that was lower than the Street had expected. The company lost NIS5.35 to NIS64.24 in Israel.

On a conference call Wednesday, President and CEO Kåre Schultz said 2019

Read the full 558 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE